Lawrence S. Lamb - Search Results

Year	Number of Results
2002	1
2003	1
2005	4
2006	1
2009	2
2010	2
2011	1
2013	4
2014	4
2015	4
2016	4
2017	1
2018	3
2019	1
2021	1
2022	1
2024	0

1

Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.

Jones AB, Rocco A, Lamb LS, Friedman GK, Hjelmeland AB. Jones AB, et al. Among authors: lamb ls. Cancers (Basel). 2022 May 9;14(9):2339. doi: 10.3390/cancers14092339. Cancers (Basel). 2022. PMID: 35565467 Free PMC article. Review.

2

Improving the safety of cell therapy products by suicide gene transfer.

Jones BS, Lamb LS, Goldman F, Di Stasi A. Jones BS, et al. Among authors: lamb ls. Front Pharmacol. 2014 Nov 27;5:254. doi: 10.3389/fphar.2014.00254. eCollection 2014. Front Pharmacol. 2014. PMID: 25505885 Free PMC article. Review.

3

Gammadelta T cells as immune effectors against high-grade gliomas.

Lamb LS Jr. Lamb LS Jr. Immunol Res. 2009;45(1):85-95. doi: 10.1007/s12026-009-8114-9. Immunol Res. 2009. PMID: 19711198 Review.

4

gammadelta T cells: a new frontier for immunotherapy?

Lamb LS Jr, Lopez RD. Lamb LS Jr, et al. Biol Blood Marrow Transplant. 2005 Mar;11(3):161-8. doi: 10.1016/j.bbmt.2004.11.015. Biol Blood Marrow Transplant. 2005. PMID: 15744234 Free article. Review.

5

Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Riley RS, Idowu M, Chesney A, Zhao S, McCarty J, Lamb LS, Ben-Ezra JM. Riley RS, et al. Among authors: lamb ls. J Clin Lab Anal. 2005;19(2):47-79. doi: 10.1002/jcla.20055. J Clin Lab Anal. 2005. PMID: 15756708 Free PMC article. Review.

6

Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field?

Siegers GM, Lamb LS Jr. Siegers GM, et al. Among authors: lamb ls jr. Mol Ther. 2014 Aug;22(8):1416-1422. doi: 10.1038/mt.2014.104. Epub 2014 Jun 4. Mol Ther. 2014. PMID: 24895997 Free PMC article. Review.

7

Persistence pays off for γδ T-cell therapies.

Lamb LS Jr. Lamb LS Jr. Cytotherapy. 2013 Apr;15(4):397-8. doi: 10.1016/j.jcyt.2013.01.013. Cytotherapy. 2013. PMID: 23480950 No abstract available.

8

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.

Lamb LS, Pereboeva L, Youngblood S, Gillespie GY, Nabors LB, Markert JM, Dasgupta A, Langford C, Spencer HT. Lamb LS, et al. Sci Rep. 2021 Oct 26;11(1):21133. doi: 10.1038/s41598-021-00536-8. Sci Rep. 2021. PMID: 34702850 Free PMC article.

9

Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting.

Chang CW, Lai YS, Westin E, Khodadadi-Jamayran A, Pawlik KM, Lamb LS Jr, Goldman FD, Townes TM. Chang CW, et al. Among authors: lamb ls jr. Cell Rep. 2015 Sep 8;12(10):1668-77. doi: 10.1016/j.celrep.2015.08.013. Epub 2015 Aug 28. Cell Rep. 2015. PMID: 26321643 Free article.

10

Clinical-scale manufacturing of γδ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis.

Lamb LS, Pillai S, Langford S, Bowersock J, Stasi AD, Saad A. Lamb LS, et al. Bone Marrow Transplant. 2018 Jun;53(6):766-769. doi: 10.1038/s41409-018-0130-8. Epub 2018 Mar 7. Bone Marrow Transplant. 2018. PMID: 29515253 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

30 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year